DexCom(US:DXCM) Globenewswire·2025-12-03 17:15Core Viewpoint - A securities fraud class action lawsuit has been filed against DexCom, Inc. for alleged misrepresentations regarding the accuracy and functionality of its Dexcom G7 continuous glucose monitoring system, impacting investors who purchased shares between January 8, 2024, and September 17, 2025 [4][5]. Group 1 - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who acquired DexCom securities during the specified period [4]. - Allegations include that the company and certain senior officers made false statements about the device's reliability and enhancements, as well as the expansion of manufacturing capabilities [5]. - Investors interested in participating as lead plaintiffs must file by December 26, 2025, although participation in any recovery does not require serving as lead plaintiff [6]. Group 2 - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success [7].